AtriCure, Inc.(ATRC)Earnings, Financials & Key Ratios

ATRC•NASDAQ

$32.80

Price updated Jul 7, 2026

SectorHealthcare IndustryMedical Instruments Sub-IndustrySurgical and interventional devices

AboutAtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.Show more

Revenue$535M+14.9%
EBITDA$17M+180.3%
Net Income-$11M+74.4%
EPS (Diluted)-0.24+74.7%
Gross Margin74.41%-0.4%
EBITDA Margin3.2%+169.9%
Operating Margin-0.64%+92.5%
Net Margin-2.14%+77.7%
ROE-2.4%+75.1%

ATRC Price & Volume

AtriCure, Inc. (ATRC) stock price & volume — 10-year historical chart

Loading chart...

Operating Leverage Inflection Amidst Competitive PFA Pressures

Investment Thesis • Updated 2026Q1

VerdictNeutral

Growth:Stable

Profitability:Moderate

Financial:Healthy

Cash Flow:Improving

Primary Risk:Competitive PFA Technology Adoption

Key Thesis Takeaways

AtriCure demonstrates consistent 14.3% revenue growth, yet the path to sustained profitability remains obscured by $11.3 million in quarterly stock-based compensation.
While the company has achieved a positive 0.4% operating margin, investors should monitor the competitive threat from Pulsed Field Ablation technologies that may pressure future pricing power.
The firm's long-term viability depends on its ability to convert high 77.4% gross margins into consistent GAAP net income while managing a significant $280.4 million goodwill balance.

Verdict Logic

while the company has reached a positive 0.4% operating margin, the high forward P/E of 845.38 and persistent reliance on external capital to offset an accumulated deficit of $413.1 million warrant a cautious, wait-and-see approach.

ATRC Growth Metrics

AtriCure, Inc. (ATRC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years15.21%

5 Years20.95%

3 Years17.4%

TTM15.01%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM87.97%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM87.93%

Return on Capital

10 Years-5.68%

5 Years-2.38%

3 Years-4.36%

Last Year-0.62%

ATRC Recent Earnings

AtriCure, Inc. (ATRC) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 10/12 qtrs (83%)●Beat Revenue 9/12 qtrs (75%)

Q2 2026Latest

May 5, 2026

Metric

Actual

Est

EPS

$0.00+103.1%

$0.07

Rev

$141M+1.1%

$140M

Q1 2026

Feb 17, 2026

Metric

Actual

Est

EPS

$0.06+249.9%

$0.04

Rev

$141M+0.6%

$140M

Q4 2025

Oct 29, 2025

Metric

Actual

Est

EPS

$0.01+90.9%

$0.11

Rev

$134M-4.4%

$141M

Q3 2025

Jul 29, 2025

Metric

Actual

Est

EPS

$0.02+86.7%

$0.15

Rev

$136M+4.6%

$130M

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	May 5, 2026	$0.00vs $0.07+103.1%	$141Mvs $140M+1.1%
Q1 2026	Feb 17, 2026	$0.06vs $0.04+249.9%	$141Mvs $140M+0.6%
Q4 2025	Oct 29, 2025	$0.01vs $0.11+90.9%	$134Mvs $141M-4.4%
Q3 2025	Jul 29, 2025	$0.02vs $0.15+86.7%	$136Mvs $130M+4.6%

Based on last 12 quarters of dataView full earnings history →

Latest ATRC News

Recent stock market news and headlines for AtriCure, Inc. (ATRC)

Business Wire·5 days ago

AtriCure to Announce Second Quarter 2026 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2026 financial results on Thursday, July 23, 2026. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Thursday, July 23, 2026, to discuss its second quarter financial results. Those interested in listeni.

GuruFocus·5 days ago

AtriCure to Announce Second Quarter 2026 Financial Results

[url="]AtriCure, Inc.[/url] ([url="]Nasdaq: ATRC[/url]), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial a

Zacks Investment Research·Jun 19, 2026

AtriCure (ATRC) Soars 6.2%: Is Further Upside Left in the Stock?

AtriCure (ATRC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Peers Comparison

Key metrics vs top competitors for AtriCure, Inc. (ATRC)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
ATRCAtriCure, Inc.Current	$32.80	$1.66B	-136.67	14.88%	-2.14%	-2.4%	—
NVCRNovoCure Limited	$17.72	$2.02B	-14.52	8.28%	-25.66%	-50.82%	—
IRTCiRhythm Technologies, Inc.	$125.09	$4.11B	-89.99	26.24%	-3.53%	-20.6%	—
BEATHeartBeam, Inc.	$0.66	$22.7M	-1.06	—	—	-1034.04%	—
ABTAbbott Laboratories	$95.84	$166.94B	25.76	5.67%	13.91%	12.09%	—
MDTMedtronic plc	$83.83	$107.63B	22.47	8.43%	13.2%	9.78%	—

Compare ATRC vs Peers

AtriCure, Inc. (ATRC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs NVCR

Most directly comparable listed peer for ATRC.

Scale Benchmark

vs JNJ

Larger-name benchmark to compare ATRC against a more recognizable public peer.

Peer Set

Compare Top 5

vs NVCR, IRTC, BEAT, ABT

ATRC SEC Filings & Documents

AtriCure, Inc. (ATRC) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

May 5, 2026·SEC

Material company update

Feb 17, 2026·SEC

Material company update

Jan 12, 2026·SEC

10-K Annual Reports

FY 2026

Feb 19, 2026·SEC

FY 2025

Feb 14, 2025·SEC

FY 2024

Feb 16, 2024·SEC

10-Q Quarterly Reports

FY 2026

May 6, 2026·SEC

FY 2025

Oct 30, 2025·SEC

FY 2025

Jul 30, 2025·SEC

Get notified when ATRC posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

ATRC Frequently Asked Questions

AtriCure, Inc. (ATRC) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

What is AtriCure, Inc.'s revenue?

AtriCure, Inc. (ATRC) reported $552.2M in revenue for fiscal year 2025. This represents a 2782% increase from $19.2M in 2004.

How fast is AtriCure, Inc. growing?

AtriCure, Inc. (ATRC) grew revenue by 14.9% over the past year. This is steady growth.

Is ATRC profitable?

AtriCure, Inc. (ATRC) reported a net loss of $4.6M for fiscal year 2025.

Dividend & Returns

What is ATRC's return on equity?

AtriCure, Inc. (ATRC) has a return on equity (ROE) of -2.4%. Negative ROE indicates the company is unprofitable.

What is AtriCure, Inc.'s free cash flow?

AtriCure, Inc. (ATRC) generated $53.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in ATRC back in 2004?

Total return calculator · dividends reinvested · 22+ years of data

See returns →

Quarter

Date

EPS (Act vs Est)

Revenue (Act vs Est)

Q2 2026Latest

May 5, 2026

$0.00vs $0.07+103.1%

$141Mvs $140M+1.1%

Q1 2026

Feb 17, 2026

$0.06vs $0.04+249.9%

$141Mvs $140M+0.6%

Q4 2025

Oct 29, 2025

$0.01vs $0.11+90.9%

$134Mvs $141M-4.4%

Q3 2025

Jul 29, 2025

$0.02vs $0.15+86.7%

$136Mvs $130M+4.6%

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

ATRCAtriCure, Inc.Current

$32.80

$1.66B

-136.67

14.88%

-2.14%

-2.4%

—

NVCRNovoCure Limited

$17.72

$2.02B

-14.52

8.28%

-25.66%

-50.82%

—

IRTCiRhythm Technologies, Inc.

$125.09

$4.11B

-89.99

26.24%

-3.53%

-20.6%

—

BEATHeartBeam, Inc.

$0.66

$22.7M

-1.06

—

-1034.04%

—

ABTAbbott Laboratories

$95.84

$166.94B

25.76

5.67%

13.91%

12.09%

—

MDTMedtronic plc

$83.83

$107.63B

22.47

8.43%

13.2%

9.78%

—